OM DENNE EPISODE

Engelsk
Det Forenede Kongerige

UDSKRIFT 🔗

SØG BLANDT TIDLIGERE EPISODER

Søg efter gamle afsnit af Oncology Talks.

ANDRE EPISODE I DENNE PODCAST

The recent buzz around CRISPR-Cas9, a genome editing tool, has revolved around its potential for treating various genetic diseases, including cancer. Jack Hopwood, Intellectual Property Consultant and Bertrand Sautier, Strategic Account Manager at Clarivate Analytics talk about how research activit…
Join Chris Willis, Manager of Discovery and Translational Sciences at Clarivate Analytics, as he talks about immuno-oncology, why it is promising for cancer patients and how it continues to evolve. Learn more about the new approved drugs on the market that treat indications of cancer and the way in…
Cancer immunotherapy research continues to evolve and offers patients a transformative alternative to traditional therapies. Anette Briendl, Senior Science Editor at BioWorld, talks about the current research landscape for immunotherapies. Learn about the challenges and potential of emerging therap…
Immuno-oncology therapies have opened up the most promising frontiers in cancer treatment today. But, with drug development costs increasing, how is it possible to maintain commercial viability? Peter Winter, Editor at BioWorld, talks about challenges to commercial viability in the immuno-oncolog…
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra Clarivate Analytics – Formerly the IP&Science business of Thomson Reuters, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.